---
reference_id: "PMID:33046911"
title: Pathogenic variants in actionable MODY genes are associated with type 2 diabetes.
authors:
- Bonnefond A
- Boissel M
- Bolze A
- Durand E
- Toussaint B
- Vaillant E
- Gaget S
- Graeve F
- Dechaume A
- Allegaert F
- Guilcher DL
- Yengo L
- Dhennin V
- Borys JM
- Lu JT
- Cirulli ET
- Elhanan G
- Roussel R
- Balkau B
- Marre M
- Franc S
- Charpentier G
- Vaxillaire M
- Canouil M
- Washington NL
- Grzymski JJ
- Froguel P
journal: Nat Metab
year: '2020'
doi: 10.1038/s42255-020-00294-3
content_type: abstract_only
---

# Pathogenic variants in actionable MODY genes are associated with type 2 diabetes.
**Authors:** Bonnefond A, Boissel M, Bolze A, Durand E, Toussaint B, Vaillant E, Gaget S, Graeve F, Dechaume A, Allegaert F, Guilcher DL, Yengo L, Dhennin V, Borys JM, Lu JT, Cirulli ET, Elhanan G, Roussel R, Balkau B, Marre M, Franc S, Charpentier G, Vaxillaire M, Canouil M, Washington NL, Grzymski JJ, Froguel P
**Journal:** Nat Metab (2020)
**DOI:** [10.1038/s42255-020-00294-3](https://doi.org/10.1038/s42255-020-00294-3)

## Content

1. Nat Metab. 2020 Oct;2(10):1126-1134. doi: 10.1038/s42255-020-00294-3. Epub
2020  Oct 12.

Pathogenic variants in actionable MODY genes are associated with type 2 
diabetes.

Bonnefond A(1)(2), Boissel M(#)(3), Bolze A(#)(4), Durand E(#)(3), Toussaint 
B(3), Vaillant E(3), Gaget S(3), Graeve F(3), Dechaume A(3), Allegaert F(3), 
Guilcher DL(3), Yengo L(3)(5), Dhennin V(3), Borys JM(6), Lu JT(4), Cirulli 
ET(4), Elhanan G(7)(8), Roussel R(9)(10)(11), Balkau B(12)(13), Marre M(10)(14), 
Franc S(15)(16), Charpentier G(15), Vaxillaire M(3), Canouil M(3), Washington 
NL(4), Grzymski JJ(7)(8), Froguel P(17)(18).

Author information:
(1)Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), 
Université de Lille, Institut Pasteur de Lille, Lille University Hospital, 
Lille, France. amelie.bonnefond@cnrs.fr.
(2)Department of Metabolism, Imperial College London, London, UK. 
amelie.bonnefond@cnrs.fr.
(3)Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), 
Université de Lille, Institut Pasteur de Lille, Lille University Hospital, 
Lille, France.
(4)Helix, San Mateo, CA, USA.
(5)Institute for Molecular Bioscience, the University of Queensland, St Lucia, 
Australia.
(6)Fleurbaix Laventie Association, Laventie, France.
(7)Desert Research Institute, Reno, NV, USA.
(8)Renown Institute of Health Innovation, Reno, NV, USA.
(9)Department of Diabetology Endocrinology Nutrition, Hôpital Bichat, DHU FIRE, 
Assistance Publique Hôpitaux de Paris, Paris, France.
(10)Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.
(11)UFR de Médecine, University Paris Diderot, Sorbonne Paris Cité, Paris, 
France.
(12)Inserm U1018, Institut Gustave Roussy, Center for Research in Epidemiology 
and Population Health, Villejuif, France.
(13)University Paris-Saclay, University Paris-Sud, Villejuif, France.
(14)CMC Ambroise Paré, Neuilly-sur-Seine, France.
(15)CERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement 
du Diabète), Evry, France.
(16)Department of Diabetes, Sud-Francilien Hospital, University Paris-Sud, 
Orsay, Corbeil-Essonnes, France.
(17)Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes 
(EGID), Université de Lille, Institut Pasteur de Lille, Lille University 
Hospital, Lille, France. p.froguel@imperial.ac.uk.
(18)Department of Metabolism, Imperial College London, London, UK. 
p.froguel@imperial.ac.uk.
(#)Contributed equally

Genome-wide association studies have identified 240 independent loci associated 
with type 2 diabetes (T2D) risk, but this knowledge has not advanced precision 
medicine. In contrast, the genetic diagnosis of monogenic forms of diabetes 
(including maturity-onset diabetes of the young (MODY)) are textbook cases of 
genomic medicine. Recent studies trying to bridge the gap between monogenic 
diabetes and T2D have been inconclusive. Here, we show a significant burden of 
pathogenic variants in genes linked with monogenic diabetes among people with 
common T2D, particularly in actionable MODY genes, thus implying that there 
should be a substantial change in care for carriers with T2D. We show that, 
among 74,629 individuals, this burden is probably driven by the pathogenic 
variants found in GCK, and to a lesser extent in HNF4A, KCNJ11, HNF1B and ABCC8. 
The carriers with T2D are leaner, which evidences a functional metabolic effect 
of these mutations. Pathogenic variants in actionable MODY genes are more 
frequent than was previously expected in common T2D. These results open avenues 
for future interventions assessing the clinical interest of these pathogenic 
mutations in precision medicine.

DOI: 10.1038/s42255-020-00294-3
PMID: 33046911 [Indexed for MEDLINE]